- MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population
- United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021
- United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021
- MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform
- NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions
- INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th
As of last trade,
MannKind Corp (NNFN:FRA) traded at 3.50, 113.08% above the 52 week low of 1.64 set on Oct 28, 2020.
1.64Oct 28 20205.55Feb 04 2021
Markit short selling activity
|Market cap||1.04bn USD|
|EPS (TTM)||-0.3625 |
Data delayed at least 15 minutes, as of Oct 20 2021 07:07 BST.